Issued 2026-08-13 at $114.03 · now $114.42 (2026-08-13, +0.3% since)
Based on its own history, a month from the 2026-08-13 close, KYMR has typically landed between $87.49 and $165.25 — a range of −23.3% to +44.9% from the issuance price $114.03.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,480 overlapping 1 month windows · 2020-08-21 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($114.03) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where KYMR has typically landed a month from the 2026-08-13 close of $114.03 — the range is history, not a prediction.
- now $114.42 (+0.3%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $112.66 (-1.2%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $97.18–$128.13
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $87.49–$165.25
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2022-04-20 | −59.7% | −59.7% | +0.0% |
| 2022-04-25 | −58.9% | −58.9% | +0.0% |
| 2022-04-19 | −58.1% | −58.1% | +0.0% |
| 3 best | |||
| 2020-11-24 | +88.0% | +0.0% | +88.0% |
| 2020-11-25 | +86.1% | −1.2% | +86.1% |
| 2023-10-27 | +83.5% | +0.0% | +90.4% |
1,480 overlapping windows · 2020-08-21 – 2026-08-13 · not cherry-picked
Pending catalysts
- June 2027 — Trial primary completion: Phase 2 primary completion: A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis (source, as of 2026-08-14)
- December 2027 — Trial primary completion: Phase 2 primary completion: A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma (source, as of 2026-08-14)
- December 2028 — Trial primary completion: Phase 2 primary completion: A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.